Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis.

Life science alliance - 1 Jun 2023

Birimberg-Schwartz Liron, Ip Wan, Bartlett Claire, Avolio Julie, Vonk Annelotte M, Gunawardena Tarini, Du Kai, Esmaeili Mohsen, Beekman Jeffrey M, Rommens Johanna, Strug Lisa, Bear Christine E, Moraes Theo J, Gonska Tanja

Abstract excerpt

Highly effective drugs modulating the defective protein encoded by the CFTR gene have revolutionized cystic fibrosis (CF) therapy. Preclinical drug-testing on human nasal epithelial (HNE) cell cultures and 3-dimensional human intestinal organoids (3D HIO) are used to address patient-specific variation in drug response and to optimize individual treatment for people with CF. This study is the first to report...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Intestines

Share to Mutation

Share to Organoids

Source

Open in PubMed Open full text

Identifiers

PMID: 37024122
DOI: 10.26508/lsa.202201857
PMCID: PMC10079552

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis.PMID 37024122Read ↗

Intestinal organoids for Cystic Fibrosis researchSemantic proximity Read ↗

Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back.Semantic proximity Read ↗

Established and novel human translational models to advance cystic fibrosis research, drug discovery, and optimize CFTR-targeting therapeutics.Semantic proximity Read ↗

Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis.Semantic proximity Read ↗

Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration.Semantic proximity Read ↗

Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic FibrosisSemantic proximity Read ↗

Patient-derived cell models for personalized medicine approaches in cystic fibrosis.Semantic proximity Read ↗

Personalized medicine for cystic fibrosis: establishing human model systems.Semantic proximity Read ↗

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.Semantic proximity Read ↗

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study.Semantic proximity Read ↗

FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis GenotypesSemantic proximity Read ↗

CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.